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Abstract
 
High systemic levels of osteoprotegerin (OPG) in OPG transgenic mice cause osteopetrosis
with normal tooth eruption and bone elongation and inhibit the development and activity of
endosteal, but not periosteal, osteoclasts. We demonstrate that both intravenous injection of re-
 
combinant OPG protein and transgenic overexpression of OPG in OPG
 
2/2
 
 mice effectively
rescue the osteoporotic bone phenotype observed in OPG-deficient mice. However, intrave-
nous injection of recombinant OPG over a 4-wk period could not reverse the arterial calcifica-
tion observed in OPG
 
2/2
 
 mice. In contrast, transgenic OPG delivered from mid-gestation
through adulthood does prevent the formation of arterial calcification in OPG
 
2/2
 
 mice. Al-
though OPG is normally expressed in arteries, OPG ligand (OPGL) and receptor activator of
 
NF-
 
k
 
B (RANK) are not detected in the arterial walls of wild-type adult mice. Interestingly,
OPGL and RANK transcripts are detected in the calcified arteries of OPG
 
2/2
 
 mice. Further-
more, RANK transcript expression coincides with the presence of multinuclear osteoclast-like
cells. These findings indicate that the OPG/OPGL/RANK signaling pathway may play an im-
portant role in both pathological and physiological calcification processes. Such findings may
also explain the observed high clinical incidence of vascular calcification in the osteoporotic pa-
tient population.
Key words: osteoprotegerin • pathologic calciﬁcation • osteoporosis • vascular disease • 
atherosclerosis
 
Introduction
 
Osteoprotegerin (OPG; also known as osteoclastogenesis
inhibitory factor [OCIF] or TNF receptor–like molecule
 
[TR1]),
 
1
 
 a member of the TNF family of receptors, is a se-
creted protein that regulates bone mass by inhibiting osteo-
clast differentiation and activation (1–3). Overexpression of
OPG in transgenic mice resulted in severe osteopetrosis as-
 
sociated with a decrease in osteoclasts in metaphyseal trabec-
ular bone (1). In contrast, OPG-deficient mice (OPG
 
2/2
 
)
exhibited an overall decrease in total bone density and a
high incidence of fractures (4, 5), reminiscent of postmeno-
pausal osteoporosis in human populations (6). The early-
onset osteoporosis observed in these mice is a result of in-
creased bone resorption associated with increased numbers
and activity of osteoclasts (4, 6).
Surprisingly, OPG
 
2/2
 
 mice also developed calcified le-
sions in the aorta and renal arteries (4). It is interesting to
note that osteoporosis in humans is associated with a higher
incidence of arterial calcification (7). Chemical composi-
tion studies indicate that these calcified vascular lesions in-
clude elements of bone matrix, such as hydroxyapatite, and
proteins of bone, including growth factors and adhesion
molecules (for review see reference 7). This dual phenome-
non of osteoporotic loss of bone mass and accumulation of
calcium minerals in arteries in the human population is an
intriguing observation which is recapitulated in OPG
 
2/2
 
mice. Although OPG is expressed in arteries (1, 4), the
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of NF-
 
k
 
B; TRAP, tartrate-resistant acid phosphatase. 
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mechanism by which it regulates pathological calcification
within the vasculature is unknown.
OPG exerts its inhibitory effects on osteoclastogenesis by
binding to OPG ligand (OPGL; also known as TRANCE,
RANKL, or osteoclast differentiation factor [ODF]), a
TNF ligand family member (8–11). OPGL directly induces
osteoclast differentiation from hematopoietic progenitor
cells in the absence of vitamin D3, stromal cells, and gluco-
corticoids in a bone marrow coculture system. It also acti-
vates mature osteoclasts both in vivo and in vitro (8). Re-
ceptor activator of NF-
 
k
 
B (RANK), a TNF receptor
family member (10), is expressed on the plasma membrane
of osteoclasts and their precursors, and is the signaling re-
ceptor for OPGL (12–14). OPG functions as a secreted in-
hibitor of the RANK signaling pathway by binding to
OPGL and competitively inhibiting the OPGL/RANK in-
teraction on osteoclasts and their precursors.
The phenotype of OPG transgenic mice differs in signif-
icant ways from other murine models of osteopetrosis (for
review see references 15 and 16). Genetic mutants such as
 
op
 
/
 
op
 
 mice (CSF-1
 
2/2
 
), microphthalmic mice 
 
(mi/mi
 
), and
c-
 
src
 
2/2
 
 and c-
 
fos
 
2/2
 
 mice all exhibit osteopetrosis accom-
panied by impaired tooth eruption and/or retarded growth.
The defects in these genetic mutants are generally associ-
ated with decreased bone resorption attributable to de-
creased osteoclast numbers or inactive osteoclasts. In gen-
eral, the long bones of the characterized osteopetrotic
mouse models are shortened in length and some mice also
exhibit modest facial and cranial abnormalities. Osteopetro-
sis in OPG transgenic founder animals was severe in high
expressors, yet occurred without shortening of the long
bones or impaired tooth eruption (1). The unique features
of the OPG osteopetrotic phenotype warrant further char-
acterization of this mouse model.
In this study, we performed detailed analysis of three
OPG transgenic lines that express different levels of OPG
and determined the temporal onset of osteopetrosis. The
analysis of these mice reveals that overexpression of OPG
specifically inhibits development and activity of osteoclasts
at the endosteal bone surface, whereas osteoclasts at the pe-
riosteal bone surface show signs of active resorption. We
also demonstrate that systemic OPG, delivered either
through injection of recombinant OPG, or through trans-
genic overexpression, rescues the osteoporosis phenotype
of OPG knockout mice. However, transient introduction
of OPG protein by injection failed to reverse the arterial
calcification observed in OPG
 
2/2
 
 mice, whereas transgenic
expression of OPG prevented the formation of calcified le-
sions in arteries of adolescent mice. Interestingly, OPGL
and RANK transcripts, which are expressed by osteoblastic
stroma and osteoclast precursors (8, 14), respectively, were
also observed in cells associated with calcified arterial le-
sions of OPG knockout mice. Multinucleated cells which
were cathepsin K
 
1
 
 and tartrate-resistant acid phosphatase
(TRAP)
 
1
 
, but F4/80
 
2
 
, were also detected, indicating the
presence of mature osteoclast-like cells in the calcified le-
sions. Taken together, these data indicate that arterial calci-
fication may involve a process similar to osteogenesis and
 
may in part be regulated by the OPG/OPGL/RANK sig-
naling pathway.
 
Materials and Methods
 
Analysis of OPG Transgenic Mice.
 
RNA analysis, necropsy,
histology, and bone density measurements were performed as
previously described (1, 4). Temporal onset of the osteopetrotic
phenotype was analyzed as follows: transgenic embryos from the
high expressing 22 line were obtained at embryonic day (E)15.5,
E16.5, and E17.5. Mice were also obtained at days 1, 4, 7, 14,
and 28 after birth. A small piece of tail tissue from each mouse
was used to identify transgenic and normal mice by PCR analysis.
Embryos and 1- and 4-d-old mice were processed whole for his-
tological assessment. Femurs and tibias of mice at days 7, 14, and
28 were removed for histology and other analysis. All procedures
involving mice were approved by the Amgen Laboratory Animal
Research Committee.
 
Ultrastructural Analysis of Osteoclasts.
 
Mice selected for elec-
tron microscopic examination were perfused with 2.5% glutaral-
dehyde and 1.6% paraformaldehyde in 0.1 M sodium cacodylate
buffer at pH 7.3. The femurs were removed and split lengthwise
and immersed in 4
 
8
 
C fixative overnight. The specimens were
then decalcified in 5% EDTA in 0.1 M sodium cacodylate buffer
with the addition of 0.1% glutaraldehyde. After 2 wk at 4
 
8
 
C, the
femurs were washed in buffer and postfixed in 1% aqueous os-
mium tetroxide before embedding in epoxy resin. 1-
 
m
 
m sections
were stained with toluidine blue. Areas selected for electron mi-
croscopy were ultra thin sectioned and collected on to 200 mesh
uncoated copper grids. The sections were stained with uranyl ac-
etate and lead citrate before examination on a Philips CM120
transmission electron microscope.
 
Treatment of OPG
 
2/2
 
 Mice with Recombinant OPG.
 
OPG
 
2/2
 
mice were generated as previously described (4) and aged to 8
wk. The severity of the phenotype in knockout mice was deter-
mined from serum alkaline phosphatase (ALP) levels obtained via
retroorbital bleeds of lightly anesthetized mice, and treatment
groups were stratified accordingly. OPG
 
2/2
 
 mice were treated
intravenously either with vehicle (PBS,
 
 n 
 
5 
 
14) or a recombi-
nant human–Fc fusion form of OPG (reference 17; 50 mg/kg
three times per week,
 
 n 
 
5 
 
13) for 4 wk. This high dose was se-
lected to maintain circulating OPG activity even if there was a
host immune response to the injected human protein. Age-
matched wild-type control mice were treated (vehicle,
 
 n 
 
5 
 
10 or
recombinant OPG,
 
 n 
 
5 
 
10) in a similar fashion. The effects of
recombinant OPG treatment were monitored via serum ALP
levels determined on day 0, before the initiation of treatment,
and on days 1, 7, 14, 21, and 28. At the conclusion of the study
all mice were radiographed with a Faxitron x-ray system
(43855A), and the tibia and the thoracic aorta were harvested,
fixed in zinc formalin, and processed for histological evaluation.
An additional tibia was harvested and fixed in 70% EtOH for
bone density analysis by peripheral quantitative computed to-
mography (pQCT).
 
Generation of OPG
 
2/2
 
 Mice Bearing OPG Transgene.
 
Male
OPG
 
2/2
 
 mice were crossed with female mice from the 22 OPG
transgenic line to generate OPG
 
1/2
 
 mice with or without trans-
gene. These F1 mice were mated to generate three groups used in
the study: OPG
 
2/2
 
 mice (
 
n
 
 5 
 
8); OPG
 
2/2
 
 mice bearing OPG
transgene (
 
n
 
 5 
 
9); and wild-type littermate controls (
 
n
 
 5 
 
10).
These mice were aged to 8 wk for necropsy and further analysis.
 
Bone Densitometry.
 
Bone mineral density was determined from
bones fixed in 70% EtOH at the proximal tibial metaphysis by 
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Figure 1. (A) Northern blot analysis of liver RNA from wild-type (line 30) and transgenic founder mice (lines 33, 22, and 45). (B) Western analysis of
OPG from serum and liver extract of line 22 transgenic mice (1) or wild-type mice (2). Chinese hamster ovary cell–produced recombinant OPG
(CHO-muOPG) is used as the positive control. (C) Hematoxylin and eosin–stained sections of femoral diaphysis from 6-wk-old wild-type (normal), low
(HECR-45), moderate (HECR-33), and high (HECR-22) OPG-expressing F1 transgenic mice. Bone stains pink, and marrow cells stain dark blue.
Green boxes represent the area used for histomorphometric quantitation of bone volume. (D) Bone volume as a percentage of tissue volume measure-
ments were made in 6-wk-old femoral diaphysis 2–4 mm from the distal growth plate, and did not include cortical bone (see C–F, above). Values are
mean 6 SEM, n 5 4–7 for F1 OPG transgenics and n 5 16 for aged-matched littermates. (E) Osteoclast number per millimeter of growth plate length
and active osteoclast surface as a percentage of growth plate length measurements were taken in the femoral metaphysis adjacent to the growth plate from
6-wk-old wild-type, low, moderate, and high OPG-expressing F1 mice. Osteoclasts considered for measurement were TRAP1 cells in contact with a
bone surface and within three cell widths of the growth plate.
 
pQCT (XCT-960M; Norland Medical Systems). Two 1-mm cross-
sections of bone were analyzed (XMICE 5.2; Stratec Corporation) at
1.5 and 2 mm from the proximal end of the tibia to determine total
(trabecular and cortical) bone mineral density, and an average value
 
for both cross-sections is reported. A soft tissue separation threshold
of 1,500 was used to define the boundary of the metaphyseal bone.
 
Histology, In Situ Hybridization, and Immunohistochemistry.
 
Sec-
tions of thoracic aorta were embedded in paraffin, sectioned on a 
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microtome, stained with hematoxylin, and counter-stained with
eosin. By this method, normal arterial smooth muscle stains light
pink, and calcified tissue stains dark blue. Bones were decalcified
with formic acid before paraffin embedding and sectioning. Tibial
sections were reacted for TRAP, which stains osteoclasts red, and
counter-stained with methyl green. Osteoclasts were counted in a
1-mm
 
2
 
 field adjacent to the metaphyseal growth plate and in a 0.5
mm 
 
3
 
 1.5 mm area of the diaphysis, 3.0 mm distal to growth
plate of the proximal tibia. Osteoblast surface area (mm) and tra-
becular bone area (mm
 
2
 
) were also determined in the same areas
of the tibia. In situ hybridization and immunohistochemistry
were performed as previously described (4, 8).
Figure 2. (A) TRAP staining
of femoral metaphysis including
the growth plate (black arrows)
from E15.5, E17.5, and 1-d-old
wild-type (WT) mice or high
OPG expressing transgenic mice
(OPG). Yellow arrowheads indi-
cate TRAP1 osteoclasts. B,
bone; M, marrow. (B) The
number of osteoclasts per milli-
meter of growth plate length was
quantitated in the metaphyseal
region of both tibias at various
ages (E15.5, E16.5, E17.5, day 1,
day 4, week 1, week 2, and
week 4). Osteoclasts considered
for measurement were TRAP
stain-positive, in contact with a
bone surface, and within the
margin of the hypertrophic carti-
lage zone. 
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Results
 
Overexpression of OPG in Transgenic Mice.
 
Three trans-
genic founder mice expressing varying levels of a rat OPG
transgene predominately in the liver (Fig. 1 A) were bred
to generate transgenic lines for analysis. High (line 22), in-
termediate (line 33), and low (line 45) expressing lines
were established where F1 offspring derived from the three
lines had different amounts of OPG protein in serum. An
ELISA for OPG protein revealed that levels of circulating
OPG spanned three orders of magnitude in the different
lines (14
 
 6 
 
4 ng/ml in line 45, 358
 
 6 
 
79 ng/ml in line 33,
and 1,112
 
 6 
 
261 ng/ml in line 22, mean
 
 6 
 
SD). The aver-
age serum OPG level in wild-type mice is 
 
,
 
1 ng/ml. The
rat protein existed as monomeric and dimeric forms in liver
extracts and serum. On nonreducing SDS-PAGE, these
forms comigrated with similar bands generated from Chi-
nese hamster ovary cell–derived murine OPG protein (Fig.
1 B). A larger, presumably trimeric form, was also evident
in serum.
Phenotypic analysis of 6–10-wk-old OPG F1 transgenic
mice revealed a profound increase in bone density in the
long bones and vertebrae (Fig. 1 C and data not shown).
Bone density correlated with levels of expression of the
OPG transgene; trabecular bone volume as a percent of tis-
sue volume in the femoral diaphysis increased from 2.64 
 
6
 
0.75% in normal littermates to 15.5 
 
6 
 
2.1% (mean 
 
6 
 
SEM)
and 79.5 
 
6 
 
2.2% with low (line 45) and high (line 22) ex-
pression of OPG respectively (Fig. 1 D). Quantitation of
osteoclasts adjacent to the distal femoral growth plate in the
primary spongiosa revealed an inverse correlation between
expression levels of OPG and osteoclast numbers (Fig. 1 E).
This is in agreement with previous data indicating that
OPG is regulating osteoclast maturation and activation (1).
 
The dense appearance of the bone was similar to other
osteopetrotic phenotypes but without endochondral club-
bing or failure of tooth eruption. Elongation of the bones
was normal in all OPG transgenic lines. In the high ex-
pressing 22 line, severe osteopetrosis was accompanied by
splenomegaly and no apparent changes in other organ sys-
tems (data not shown). To address how normal bone elon-
gation in OPG transgenic mice occurred even in the pres-
ence of severe osteopetrosis, the temporal onset of the
osteopetrotic phenotype was examined in the high express-
ing 22 line. Expression of OPG mRNA was detected in
embryonic liver at E12.5 (data not shown). Increased endo-
chondral bone density was apparent by x-ray on E17.5
(data not shown) and by histology at birth (Fig. 2 A).
Transgenic F1 progeny were clearly osteopetrotic on post-
natal day 4, with progressive filling of the femoral medul-
lary cavity with dense trabecular bone evident through
postnatal day 28. Tooth eruption occurred normally in
OPG transgenic mice. The mice exhibit normal growth
rates and no signs of infertility past 1 yr of age. The late em-
bryonic and postnatal increases in bone density were pre-
ceded and accompanied by reduced numbers of osteoclasts
adjacent to hypertrophic chondrocytes below the metaphy-
seal growth plates of endochondral bones (Fig. 2 B).
Clearly, in transgenic mice, OPG exerts its inhibitory ef-
fects on osteoclasts during the bone elongation and growth
period. Thus, normal bone elongation in these mice occurs
despite the early developmental onset of osteopetrosis.
Electron microscopy analysis of osteoclast structure pro-
vided insight into the osteopetrosis observed in OPG trans-
genic mice. Analysis of ultrastructural features of osteoclasts
on the femoral endosteal bone surface indicates that trabecu-
Figure 3. (A) Activated osteoclast in the process of resorbing trabecular bone in the region of the diaphyseal–epiphyseal junction of the proximal femur
of a wild-type mouse. The asterisks indicate lysosomal vacuoles, and the arrows indicate the formation of a ruffled border. (B) Resting or inactive osteo-
clast adjacent to trabecular bone from the region of the diaphyseal-epiphyseal junction of the proximal femur of an OPG transgenic mouse. (C) Activated
osteoclast in a resorption lacuna on the periosteal femoral cortical bone of OPG transgenic mice. Note the formation of lysosomal vacuoles and a ruffled
border. Bars: A and B, 2.5 mm; C, 5.0 mm. 
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lar osteoclasts in OPG transgenic mice show no evidence of
active bone resorption or interaction with the bone surface
(Fig. 3, compare A with B). Endosteal osteoclasts in OPG
transgenic mice show no evidence of ruffled borders, How-
ship’s lacunae, or vacuoles, all of which are evident in multi-
nucleated osteoclasts actively resorbing bone in control mice.
Mitochondria and lysosomes are abundant in the transgenic
osteoclasts, and in this regard are similar to the activated os-
teoclasts seen in control mice. Interestingly, osteoclasts are
abundant in OPG transgenic mice on periosteal bone sur-
faces adjacent to the growth plate, where active modeling or
sculpting of bone occurs. In addition, osteoclasts on the peri-
osteal surface of cortical bone show signs of active bone re-
sorption (Fig. 3 C), indicating that OPG transgenic mice
have a specific defect in endosteal osteoclast development.
This finding is consistent with the previous observations that
local levels of OPGL on the periosteal bone surface are rela-
tively high compared with levels of OPGL on endosteal tra-
becular bone (8). The levels of OPG expression in these
transgenic mice may be sufficient to block OPGL/RANK
interactions in the endosteal envelope, yet may not be suffi-
cient to block the high levels of OPGL present on periosteal
bone surfaces, even in the highest expressing mice.
 
Rescue of the Osteoporosis in OPG Knockout Mice.
 
In
contrast to the phenotype of OPG transgenic mice, OPG
 
2/2
 
mice develop severe osteoporosis associated with increased
number of osteoclasts (4). Osteoblast surfaces are also in-
creased, indicating an increase in bone turnover rate that is
presumably secondary and compensatory for the increased
bone resorption. Interestingly, approximately two-thirds of
OPG null mice also develop calcified lesions in the aorta and
renal arteries (4). Since OPG mRNA expression is detected
in bones as well as major arteries, we used two methods to
investigate whether circulating OPG can rescue the bone
and arterial phenotypes of OPG knockout mice. First, OPG
transgenic mice were bred with OPG knockout mice to test
the prophylactic capabilities of systemic OPG. We also
tested the effects of OPG after the onset of osteoporosis and
arterial calcification by injection of recombinant OPG pro-
tein into 8-wk-old OPG
 
2/2
 
 mice.
High expressing OPG transgenic mice were bred into
the OPG null background. Histological analysis of the
metaphyseal region of the femur shows that 8-wk-old
OPG
 
2/2
 
 mice exhibit severe osteoporosis characterized by
a significant decrease in trabecular bone density compared
with wild-type mice (Fig. 4, compare A and B). In con-
Figure 4. (A–C) Hematoxylin
and eosin stained sections of the
distal femur of (A) wild-type, (B)
OPG2/2 mice, and (C) OPG2/2
mice bearing OPG transgene.
OPG2/2 mice (B) show os-
teoporotic bone structure and
lack of secondary spongiosa
compared to wild-type (A). Os-
teopetrosis occurs in OPG2/2
mice bearing OPG transgene
(C). (D–F) Polarized light mi-
croscopy of the cortical bone in
mid-femoral diaphysis in wild-
type mice (D), OPG2/2 mice
(E), and OPG2/2 mice bearing
OPG transgene (F). Note the
woven bone in OPG2/2 mice
(E), a characteristic of high bone
turnover rate, compared to
highly lamellar bone of OPG2/2
mice bearing OPG transgene
(F). (G–I) TRAP-stained sec-
tions of wild-type mice(G),
OPG2/2 mice (H), and OPG2/2
mice bearing OPG transgene (I).
Note the significant increase in
osteoclasts (black arrows) in
OPG2/2 mice (H) compared
with OPG2/2 mice bearing
OPG transgene (I). The visible
increase in osteoblasts (yellow
arrowheads) indicates a compen-
satory increase in bone forma-
tion in OPG2/2 mice. 
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trast, transgene-expressing OPG2/2 mice exhibit significant
increases in trabecular bone density (Fig. 4 C), close to the
severity of osteopetrosis observed in high expressing OPG
transgenic mice on the wild-type background (Fig. 1). The
increase in bone density is also apparent on the whole body
radiographs of mice from different groups (data not
shown). The bone density in each group was quantified by
pQCT measurements (18). Total bone density in OPG2/2
mice is 353 6 29 mg/cm3 versus 426 6 39 mg/cm3 in
wild-type mice (P , 0.005). OPG2/2 mice bearing the
transgene showed significantly increased total bone density
of 637 6 59 mg/cm3 (P , 0.005), which is comparable to
bone density observed in wild-type mice bearing the trans-
gene (4). These data indicate that circulating OPG can in-
crease overall bone density independent of endogenous
OPG expression.
Increased bone density in OPG2/2 mice bearing the
transgene can be attributable to decreased bone resorption.
Polarization microscopy of the femoral cortical bones of
these mice showed a highly lamellar collagen deposition
Figure 5. 4-wk treatment of
8-wk-old OPG2/2 and wild-
type mice with human OPG–Fc
fusion protein (50 mg/kg, three
times per week) increases bone
density. (A–D) Radiographs of
the hind limbs of OPG2/2 (A
and B) and wild-type (C and D)
mice treated with either vehicle
(A and C) or OPG–Fc protein
(B and D). Yellow arrows indi-
cate area where increase in bone
density is apparent after OPG
treatment. (E–H) Computed tomographic images of OPG2/2 (E and F) and wild-type
(G and H) mice generated from a 1-mm cross-section of bone 2 mm distal to the prox-
imal articular surface of the tibia. White indicates the areas of greatest bone mineral con-
tent. Note the increase in the bone mineral content in OPG–Fc–treated mice (F and H)
compared with vehicle-treated mice (E and G). (I) Bone density, as determined by
pQCT of OPG2/2 and wild-type mice, is increased in the proximal tibia after 4 wk of
OPG treatment. (J) Osteoclast number per mm2 bone (NOc/BA) and osteoblast surface
relative to bone surface (ObS%BS) are increased in OPG2/2 mice compared with wild-
type controls. Treatment of these mice with OPG–Fc for 4 wk suppresses these markers
of bone metabolism to subphysiologic levels. (K) Serum ALP levels in OPG2/2 mice are
elevated, indicating the systemic nature of the increased bone turnover. 3 d after begin-
ning treatment with OPG–Fc protein, serum ALP levels in OPG2/2 mice fall to within
the normal range and remain decreased for the duration of the treatment period. (Mean 6
SEM, asterisk indicates P , 0.01 compared with OPG2/2; No. symbol indicates P ,
0.01 compared with wild-type.)470 OPG in Osteoporosis and Arterial Calcification
pattern, consistent with a slow remodeling rate (Fig. 4 F).
This is in contrast to the woven bone observed in OPG2/2
mice. The rate of bone turnover is also reflected in osteo-
clast and osteoblast numbers (data not shown). Histological
staining reveals decreased levels of osteoclasts and osteo-
blasts in OPG2/2 mice bearing the transgene compared
with OPG2/2 mice (Figs. 4, H and I). Thus, systemic OPG
expression starting from E12 prevents the onset of the os-
teoporotic phenotype of OPG2/2 mice by decreasing the
rate of bone resorption, and also results in bone of more or-
dered lamellar structure by reducing bone remodeling.
To test effects of systemic OPG after onset of the os-
teoporotic phenotype, recombinant human OPG–Fc fu-
sion protein was injected intravenously into 8-wk-old
OPG2/2 mice. These mice were treated at a dose of 50
mg/kg per day, three times per week, for 4 wk. The OPG-
injected knockout mice show a significant increase in bone
density compared with mock-treated OPG2/2 mice as in-
dicated by radiographic analysis (Fig. 5, A–D). As controls,
wild-type mice were also injected either with recombinant
OPG or with PBS solution. The increased bone density
was most prominent in the metaphysis of long bones, sites
of growth-related remodeling, but was also evident in the
shafts of long bones. pQCT analysis at the proximal tibial
metaphysis showed that trabecular bone density in the
OPG injected OPG2/2 mice is 641 6 42 mg/cm3 versus
238 6 16 mg/cm3 in the mock-treated OPG2/2 mice (Fig.
5, E, F, and I). The wild-type control groups showed tra-
becular densities of 394 6 39 mg/cm3 in mock-treated ver-
sus 639 6 51 mg/cm3 in OPG-treated mice (Fig. 5, G–I).
The increased bone density in OPG-injected mice can be
correlated with decreased bone resorption as osteoclast
numbers are markedly decreased. The rate of bone forma-
tion also is very likely reduced, as osteoblast numbers are
significantly lower in OPG-injected groups than in mock-
treated groups (Fig. 5 J). The serum ALP level in OPG2/2
mice is elevated to z400 IU/liter compared with 100–150
IU/liter in wild-type mice, probably due to increased os-
teoblast activity in OPG2/2 mice (Fig. 5 K). After com-
mencement of treatment with recombinant OPG in
OPG2/2 mice, serum ALP levels decreased to 158 IU/liter
within 3 d, and further injections caused an additional de-
crease in ALP to wild-type levels. Clearly, systemic OPG
can decrease bone resorption and reverse the osteoporotic
phenotype of OPG2/2 mice, and this is associated with a
decrease in the rate of bone turnover.
Effects of OPG on the Calcified Lesions of OPG Knockout
Mice. Previously, we showed that approximately two-
thirds of OPG2/2 mice develop calcified lesions in large ar-
teries, including the aorta and renal arteries (4). In recombi-
nant OPG injection experiments, 9 out of 14 OPG2/2
mice injected with recombinant protein still showed inci-
dence of aortic calcification (Fig. 6 C). 9 out of 13 OPG2/2
mice in the PBS-treated control group exhibited calcified
lesions in the aorta (Fig. 6 B). Thus, 4 wk of continuous
treatment of OPG did not reduce the incidence of aortic
calcification. In contrast, among eight OPG2/2 mice ex-
pressing the ApoE–OPG transgene, none showed any cal-
cification in major arteries (Fig. 6 F). Five out of eight
OPG2/2 mice from the same litters showed calcified lesions
as expected (Fig. 6 E). Taken together, these results indicate
that circulating OPG has preventative, but not reversing ef-
fects on the formation of arterial calcified lesions. Timing of
OPG administration could influence the severity of arterial
calcification.
Closer examination of OPG knockout mice revealed the
presence of large multinucleated cells associated with calci-
fied arteries (Fig. 7 D). Interestingly, in situ analysis showed
that RANK is expressed in these cells, whereas little or no
RANK expression was observed in uncalcified regions of
arteries of OPG2/2 mice and in arteries of wild-type mice
(Fig. 7, compare F with C). OPGL expression is also de-
tected above background in this region, possibly on cells
with close proximity to the large multinucleated cells (Fig.
7, compare E with B). Since OPGL and RANK have been
shown to be expressed by cells of the osteoblast and osteo-
clast lineages, respectively, we were curious about the na-
ture of cells in calcified areas of the OPG2/2 arterial wall.
Calcified lesions have been shown to contain cells express-
ing many osteoblast markers, including hydroxyapatite, os-
teocalcin, collagen type I, and osteopontin (19–24). How-
Figure 6. (A–C) Effects of recombinant OPG–Fc protein on calcified
aorta of OPG2/2 mice. Hematoxylin and eosin–stained sections of the de-
scending thoracic aorta of (A) age-matched wild-type mice, (B) OPG2/2
mice treated with PBS, and (C) OPG2/2 mice treated with OPG–Fc (50
mg/kg three times per week) are shown. Calcified lesions are indicated by
black arrowheads and dark purple staining. Note that protein therapy with
OPG–Fc does not have any effect on arterial calcification. (D–F) Effects of
transgenic OPG expression on aorta of OPG2/2 mice. Aortic sections of
(D) wild-type mice, (E) OPG2/2 mice, and (F) OPG2/2 mice bearing
OPG transgene. Note the absence of the calcified lesions in F.471 Min et al.
ever, the presence of osteoclasts or their equivalent in
calcified lesions of the arterial wall has not been well char-
acterized to date. Many multinucleated cells associated with
RANK expression within the calcified lesions of OPG2/2
arteries were TRAP1 and Cathepsin K1 (Fig. 8, A–C).
These TRAP1 and Cathepsin K1 multinuclear cells were
negative for F4/80, a macrophage marker (data not
shown). Thus, these multinucleated cells behave very simi-
lar to mature osteoclasts. The calcification-associated cell
mass contained other cell types as well. Some multinucle-
ated cells were negative for TRAP, Cathepsin K, and F4/
80 stains and thus could not be identified (Fig. 8 D). How-
ever, CD31 T cells and F4/801 macrophages were present,
indicating an inflammatory response (Fig. 8, E–H).
Discussion
Transgenic mice expressing OPG under the control of
the human apolipoprotein E gene promoter and its liver-
specific enhancer exhibit severe osteopetrosis (1). Circulat-
ing OPG in these mice functions by inhibiting osteoclast
differentiation from hematopoietic monocyte/macrophage
precursor cells and by inhibiting activation of existing os-
teoclasts. Other mouse osteopetrotic models characterized
to date contain loss-of-function mutations that affect osteo-
clast development or function (for review see reference
16). A major phenotypic difference between OPG trans-
genic mice and other osteopetrotic models is the absence of
impaired tooth eruption and “clubbing” of long bones,
which occur in all the mutant models.
Analysis of three transgenic lines that overexpress OPG
reveal that the severity of osteopetrosis correlates directly
with serum OPG levels. High expressing lines exhibited
the most drastic phenotype with no discernible open mar-
row space in the midshaft region of long bones. In the two
Figure 7. The expression of OPGL and RANK mRNAs near calcified
lesions by in situ hybridization. (A–C) Normal appearance of and OPGL/
RANK expression in murine aortic tissue. (A) Hematoxylin and eosin–
stained section of smooth muscle in the aortic wall of wild-type mice. (B)
OPGL and (C) RANK are not normally expressed in adult murine aortas.
(D–F) Calcified lesion in OPG2/2 mice associated with large multinuclear
cells (yellow arrows) and OPGL/RANK mRNA expression. (D) Hema-
toxylin and eosin–stained section of calcified lesion in the aortic wall of an
OPG2/2 mouse. (E) OPGL and (F) RANK mRNAs are detectable by in
situ hybridization in the calcified regions where multinucleated cells are
present (D). Figure 8.  Immunohistochemistry showing the presence of osteoclast-
like cells (Cathepsin K1 and TRAP1) and T cell infiltrates (CD31) in cal-
cified lesions of OPG2/2 mice. Large multinuclear cells (A–D, yellow ar-
rows associated with calcified lesions are apparent with hematoxylin and
eosin staining (A). Some of these cells stain positive with a Cathepsin K
antibody (B) and TRAP stain (C). (D) Other large multinuclear cells are
not positive for Cathepsin K, TRAP, or F4/80 macrophage marker
(Cathepsin K immunohistochemistry is shown), thus the identity of these
cells could not be determined. (E–H) Calcified regions of OPG2/2 aortas
are also associated with infiltrates of inflammatory cells that are apparent
with (E) hematoxylin and eosin staining. These infiltrates primarily con-
sist of CD31 T cells (F) with a few F4/801 macrophages (G, black ar-
row). These cells did not overlap with Cathepsin K1 cells (H).472 OPG in Osteoporosis and Arterial Calcification
highest expressing lines, the histological appearance of en-
dochondral growth plates paralleled those in classical osteo-
petrosis, being characterized by the presence of cartilage
remnants from the primary spongiosa seen encased in bone
in the diaphysis of the femur. It is not likely that the phe-
notypic differences that are observed between OPG trans-
genic mice and other osteopetrotic models are due to a dif-
ference in severity of osteopetrosis. Onset of osteopetrosis
in OPG transgenic mice is evident at E17.5 and progresses
during the postnatal bone growth and elongation period,
indicating that temporal exertion of OPG’s osteoclast in-
hibitory effect also is not responsible for the phenotypic
differences. Electron microscopy analysis revealed an im-
portant difference in the osteoclast populations of OPG
transgenic mice. The few trabecular osteoclasts present in
the OPG transgenic mouse bones appear morphologically
inactive, lacking vacuolated spaces and failing to form re-
sorptive pits on the bone surface. In contrast, osteoclasts at
the periosteal bone surface were numerous and exhibited
active signs of bone resorption.
The most likely explanation for the differences between
endosteal trabecular osteoclasts and periosteal osteoclasts is
that transgenic delivery of OPG to the periosteal envelope
is insufficient to completely block OPGL on periosteal
bone, where high levels of OPGL interact in a juxtacrine
fashion with RANK on osteoclast precursors. In contrast to
OPG transgenic mice, other mouse osteopetrosis models,
such as op/op mice (CSF-12/2), microphthalmic mice (mi/
mi), and c-src2/2 and c-fos2/2 mice, contain loss-of-function
mutations, and all osteoclasts in both the endosteal and pe-
riosteal envelopes are defective in different stages of differ-
entiation and activation (for review see references 15 and
16). Alternatively, the periosteal osteoclasts in OPG trans-
genic mice may be functional because OPG is specific only
for a subpopulation of osteoclasts resident in the endosteal
envelope. In this scenario, OPG could control the specific
regulatory pathway in trabecular endosteal osteoclasts and
thus bypass the stimulation of bone resorption for tooth
eruption and periosteal remodeling of the long bones.
However, OPGL-deficient mice have been generated re-
cently and exhibit a classic osteopetrosis phenotype with
defective tooth eruption and shortened and club-shaped
long bones due to complete lack of mature osteoclasts (25).
These results suggest that the pathway regulated by OPG
affects the differentiation of all, rather than a subpopulation
of, osteoclasts. The unique features of the osteopetrosis ob-
served in the OPG transgenic mice may result from differ-
ences in the ability of systemic OPG to effectively inhibit
local concentrations of OPGL on different bone surfaces.
Consistent with osteopetrosis observed in OPG trans-
genic mice, the OPG2/2 mice exhibited severe osteoporo-
sis characterized by trabecular and cortical bone porosity,
thinning of parietal bones, and a high incidence of fractures
(4). Unexpectedly, OPG2/2 mice also exhibited an increase
in vascular calcification in the aorta and renal arteries. Since
OPG is expressed in bone as well as major arteries, it was
not clear what effect circulating OPG would have on the
osteoporosis and calcified lesions observed in OPG2/2
mice. We show that high levels of circulating OPG ex-
pressed as a transgene on the OPG null background re-
sulted in osteopetrosis. Injection of recombinant OPG into
osteoporotic OPG2/2 mice resulted in an increase in trabec-
ular bone associated with a decreased bone turnover rate.
These results suggest that circulating OPG can be used as a
therapeutic agent to treat osteoporosis before and after the
onset of osteolytic disease. Recently, OPG was shown to
protect against bone loss caused by various resorptive hor-
mones and cytokines, such as IL-1b, TNF-a, parathyroid
hormone (PTH), parathyroid hormone related peptide
(PTHrp), and 1a,25-dihydroxyvitamin D3 (17). All of
these factors are implicated in human bone disease associ-
ated with increased osteoclast activity, such as postmeno-
pausal osteoporosis, localized bone loss in rheumatoid ar-
thritis, osteoitis fibrosa associated with renal failure, and
hypercalcemia in hyperparathyroidism, sarcoid, and cancer.
Hence, OPG could have utility in multiple clinical indica-
tions as a therapeutic agent against bone loss.
The aorta and renal arteries are sites of endogenous OPG
expression, and it is these arteries that develop calcified le-
sions in OPG-deficient mice (4). These arteries are also the
sites most frequently exhibiting calcification in human pa-
tients with atherosclerosis. However, the calcification in
OPG knockout mouse arteries occurs in the absence of fat
deposition and other vascular lesions commonly seen in
atherosclerosis patients. Furthermore, although pathologi-
cal calcification of arteries occurs late in the atherosclerotic
process, the onset of arterial calcification is early in the
OPG knockout mice. The rescue experiments show that
expression of OPG as a transgene on an OPG null back-
ground prevented the onset of arterial calcification, indicat-
ing that systemic OPG plays a protective role in major ar-
teries. However, injection of a high dose of recombinant
OPG into adult OPG2/2 mice did not affect the incidence
of arterial calcification, indicating that OPG cannot reverse
the calcification process. It is not clear from our data
whether the size of calcified lesions stopped increasing in
the OPG-injected group. Delivery of OPG to younger an-
imals, or treatment for .4 wk, will be necessary to deter-
mine whether OPG can stop further progression of vascu-
lar calcification.
Areas of arterial calcification have been reported to show
similar morphological characteristics to lamellar bones, such
as trabeculae, lacunae, and islands of marrow (26, 27). Cal-
cified lesions have also been shown to contain many of the
bone matrix proteins, such as collagen type I, osteocalcin,
osteonectin, osteopontin, matrix g-carboxyglutamic acid
(GLA) protein, and bone morphogenic protein 2 (20–22).
Watson et al. have previously defined a population of aortic
cells that spontaneously calcify in vitro, which they termed
calcifying vascular cells (28). These cells produce osteo-
blast-specific markers, including osteocalcin and hydroxy-
apatite. Consistent with these observations, cells in the calci-
fied lesions of OPG2/2 arteries express OPGL, a molecule
expressed on osteoblastic stroma (8). Although these cells
could represent calcifying vascular cells, we cannot rule out
the possibility that the OPGL1 cells detected in the arteries473 Min et al.
of OPG2/2 mice are T cells or some other cell type. The
presence of functional osteoclasts in calcified arteries has
been questionable thus far. At least some multinucleated
cells in the calcified arteries of OPG2/2 mice are positive
for TRAP stain as well as for Cathepsin K, and negative for
F4/80, which is typical of osteoclasts. Furthermore,
RANK, which is expressed in osteoclasts and their precur-
sors (14), was also detected by in situ in the cell mass associ-
ated with calcified lesions. These findings indicate the pres-
ence of osteoclasts or osteoclast-like cells in the calcified
lesions, suggesting that vascular calcification may result in a
process involving cellular mechanisms similar to those ex-
hibited during physiological calcification processes.
Genetic studies using inbred mice have suggested that
multiple genes are involved in formation of aortic calcifica-
tion (29). Several loss-of-function mutations in both hu-
man and mouse extracellular matrix (ECM) protein genes
suggest that ECM calcification is a passive process and “ac-
tive inhibition” is necessary to avoid pathological calcifica-
tion (for review see reference 30). The most prominent ex-
ample is the matrix GLA protein–deficient mice. Unlike
the OPG2/2 mice, these mice show extensive calcifications
not only in major arteries but also in muscular arteries and
cartilage (31). Although OPG is not an extracellular matrix
protein, it does seems to be involved in active inhibition of
calcified lesion formation in arteries. Not only endogenous
OPG but also systemic OPG in the OPG2/2 background
can actively inhibit calcification in arteries. OPG therapy in
the osteoporotic population may potentially lower the inci-
dence of arterial calcification.
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